C-QWVDCaraway Therapeutics
medicines, vaccines, clinical trials
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QWVD
C-QWVDC-QWVDmedicines, vaccines, clinical trials
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
#MRK Merck 2025 Q4 & Full Year Earnings: Merck reported strong Q4 2025 results with a non-GAAP EPS of $2.04, slightly beating forecasts, driven by robust sales in oncology and animal health. - Revenue: $16.4 billion - Adj. EPS: $2.04 vs. forecast $2.03 (8 analysts) - Full-Year Sales: $65.0 billion - 2026 Sales Outlook: $65.5B-$67.0B - 2026 Non-GAAP EPS Outlook: $5.00-$5.15 "In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the world," said Robert M. Davis, chairman and chief executive officer. If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover. *Check out our latest videos on more earnings:* - #EPD Enterprise Products Partners 2025 Q4 Earnings: https://www.youtube.com/watch?v=3
The FDA has approved the injectable version of Merck’s cancer therapy Keytruda. Merck CEO Robert Davis discusses the pricing of this drug and others with CNBC’s Angelica Peebles, Joe Kernen, Becky Quick, and Andrew Ross Sorkin. Davis also stands firm on the safety of vaccines and weighs in on the Trump administration’s agenda for health care. Jimmy Kimmel has returned to ABC’s airwaves. Puck’s Matt Belloni discusses the host’s temporary suspension, Kimmel’s response, and the contractual obligations of Disney’s affiliates Nexstar and Sinclair. Plus, the U.S. has barred Iran’s diplomats from shopping at wholesale stores like Costco without permission. In this episode Matt Belloni, @mattbelloni Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Katie Kramer, @Kramer_Katie For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: http
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC on Threads: https://cnb.cx/threads Follow CNBC News on X: https://cnb.cx/FollowCNBC Follow CNBC on WhatsApp: https://cnb.cx/WhatsAppCNBC https://www.cnbc.com/select/best-credit-cards/
Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business, the company's drug pipeline outlook, and more.
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. For more on this story, please see: https://www.bloomberg.com/news/articles/2024-03-26/merck-drug-for-rare-high-blood-pressure-disorder-approved-in-us
Chief executives from three major pharmaceutical companies are testifying before the Senate health committee on Thursday on drug prices. Johnson & Johnson CEO Joaquin Duato, Merck CEO Robert Davis and Bristol Myers Squibb CEO Chris Boerner are appearing before the panel chaired by Vermont Sen. Bernie Sanders. #news #senate #pharma CBS News Streaming Network is the premier 24/7 anchored streaming news service from CBS News and Stations, available free to everyone with access to the Internet. The CBS News Streaming Network is your destination for breaking news, live events and original reporting locally, nationally and around the globe. Launched in November 2014 as CBSN, the CBS News Streaming Network is available live in 91 countries and on 30 digital platforms and apps, as well as on CBSNews.com and Paramount+. Subscribe to the CBS News YouTube channel: https://youtube.com/cbsnews Watch CBS News: https://cbsnews.com/live/ Download the CBS News app: https://cbsnews.com/mobile/ Follo
Rob Davis (JD ‘98, MBA ‘93), who serves as Chairman and CEO of Merck & Co., reflects on how health has profoundly influenced his life. Growing up in a small farming town, success appeared to hinge on either becoming a doctor or a lawyer. Davis recounts a poignant moment with the former CEO of Merck that inspired him to join the company.
Merck chairman and CEO Rob Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil, but posted a quarterly loss due to its acquisition of the biotech company Prometheus Biosciences earlier this year. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).
Merck CEO Robert Davis joins CNBC's 'Squawk Box' to break down the company's third-quarter earnings report, which beat Wall Street's estimates on Thursday. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on
Merck CEO Robert Davis sits down with CNBC's Meg Tirrell and the 'Squawk Box' team to discuss the company's forecasted sales for its Covid-19 pill molnupiravir. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC
Merck CEO Rob Davis discusses the need to distribute its Covid-19 anti-viral drug around the world, how it's priced and the importance of vaccine development. He speaks on "Bloomberg Surveillance."
Merck & Co. Chief Executive Officer Rob Davis discusses the efficacy of the firm's Covid-19 treatment pill and efforts to meet the U.S. government's order of the antiviral on "Bloomberg Markets: European Close."
Merck, the maker of a pill designed to treat COVID-19, announced its third-quarter financial results Thursday. According to the company, sales in Q3 were 20% higher than they were in Q3 of 2020. Net income jumped 55% to $4.57 billion. “Merck delivered another strong quarter with positive momentum across our business and meaningful progress across our pipeline,” Merck President/CEO Rob Davis said. “Our team continued to excel as we focus on evolving our operations, while driving innovations in our labs that exemplify the best of Merck science.” The COVID-19 pill maker saw its stock jump 4% at the start of the trading day Thursday. In its Q3 results, Merck said it “expects full-year 2021 sales growth of 14% to 15%”. Merck’s COVID-19 pill, called molnupiravir, did not factor in the company’s Q3 numbers. However, the pill could soon add to the company’s revenue. Merck has asked regulators in both the U.S. and Europe for authorization of the pill, which has been shown to cut COVID-19 hos
CNBC's Meg Tirrell sits down with Merck CEO Robert Davis to discuss the company's latest earnings beat and its experimental Covid-19 pill. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi Merck CEO Robert Davis told CNBC on Thursday the drugmaker is ready to produce and distribute tens of millions of doses of its Covid antiviral pills if given regulatory approval. “Right now, we’re on pace to have 10 million courses ready before the end of this year, and more than double that next year,” Merck CEO Robert Davis told “Squawk Box.” A Food and Drug Administration advisory committee is scheduled to the evaluate safety and efficacy data of the pill, known as molnupiravir, on Nov. 30 and decide whether or not to approve it for emergency use authorization in the U.S. Merck and its partner Ridgeback Biotherapeutic said that internal data indicated that the risk of hospitalization or death from Covid was cut in half by molnupiravir. Patients take
Johns Hopkins University was honored to welcome Merck CEO Robert M. Davis for a virtual conversation with Carey Business School Dean Alex Triantis as part of the Johns Hopkins Health Policy Forum series on Oct. 4, 2021. The conversation covered a range of topics, including Merck’s role in the fight against the COVID-19 pandemic, the power of public-private partnerships in driving policy change, and a reflection on Merck’s legacy of leadership in advancing drug affordability policies and actions around the world. About the series The series is jointly hosted by the Bloomberg School of Public Health, the School of Nursing, the Carey Business School, and Johns Hopkins Medicine. The forum provides an opportunity for Johns Hopkins faculty, students, and operational experts to engage with policy makers and explore contemporary health policy approaches. More information and archive videos can be found here: https://hub.jhu.edu/johns-hopkins-health-policy-forum-series/
Merck & Co. shares posted their biggest gain in 12 years after the company’s experimental pill slashed the risk of getting seriously ill or dying from Covid-19 in a study, findings that could eventually yield a simple way to treat many virus patients before they ever reach the hospital. The drug, known as molnupiravir, reduced the risk of hospitalization or death by 50% in an interim analysis of a late-stage clinical trial, Merck and partner Ridgeback Biotherapeutics LP said in a statement on Friday. The study results were so encouraging that Merck and closely held Ridgeback, in consultation with independent trial monitors and the U.S. Food and Drug Administration, elected to stop enrolling patients and begin the process of gaining regulatory clearance. “We couldn’t be more thrilled with the results,” Merck Chief Executive Officer Rob Davis said in an interview. “You don’t have to go to the hospital, you don’t have to go to a center to have it infused. It’s a pill you can take at h
Merck CEO Rob Davis joins CNBC's "Squawk Box" and Meg Tirrell to provide an update on the company's highly anticipated Covid-19 pill molnupiravir, which is in late-stage testing. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast Connect with CNBC News Online Get the latest news: ht
Merck is set to acquire Acceleron Pharma for $180 a share. CNBC's Meg Tirrell spoke with Robert Davis, Merck CEO and president, about the upcoming data regarding the company's new Covid antiviral pill and the Merck-Acceleron Pharma deal. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodca
Merck CEO Ken Frazier will retire effective June 30 and will be replaced with the company’s CFO Robert Davis, the company announced on Thursday. CNBC's "Squawk Box" crew discusses. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi Merck’s outspoken chairman and CEO, Ken Frazier, is retiring after almost 30 years at the drugmaker, the company announced Thursday. Frazier, 66, will be succeeded as CEO on June 30 by Chief Financial Officer Robert Davis and will continue to serve on Merck’s board as executive chairman “for a transition period to be determined by the board,” the company said. Frazier, one of the few Black corporate leaders in the United States, has been Merck’s chief since January 2011. “It has been a privilege to serve as Merck’s CEO for the past decade and to work with the most dedicated and talented employees and management team in the industry,” Frazier said in the statement. “As executive chairman, I look forward to colla
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse. The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard chemotherapy treatment.
The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying Drug (DMD) (Interferons, Glatiramer Acetate, Teriflunomide, (Dymethyl fumarate) \[DMF\]) to treatment with Cladribine tablets in routine clinical practice.
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics (PK), and preliminary antitumor activity of intratumoral (IT) / intralesional injections of MK-4621 delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
The study will be conducted in participants with symptomatic knee OA to explore the safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of MAD of M6495.
The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma. Participants will be randomized to receive either pembrolizumab or brentuximab vedotin (BV) for up to 35 three-week cycles of treatment. The primary hypotheses of this study are that treatment with pembrolizumab prolongs Progression-free Survival (PFS) and Overall Survival (OS) in participants with relapsed or refractory Classical Hodgkin Lymphoma compared to treatment with BV.
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that after 30 weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C (A1C) relative to withdrawing sitagliptin.
This is a randomized, multi-site, open-label trial of the co-administration of a fixed-dose combination (FDC) of EBR 50 mg + GZR (100 mg) (EBR/GZR) and SOF 400 mg, with and without RBV, in treatment-naïve (TN) and treatment-experienced (TE) participants with chronic HCV GT3 infection with compensated cirrhosis.
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study was to demonstrate consistency in the immune responses of participants receiving 3 separate lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose group and a placebo group were studied. A subset of participants representative of all treatment groups continued through 24 months postvaccination in the extension study for the evaluation of long-term safety. The primary hypothesis states that the geometric mean titer of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is equivalent across the three consistency lots.
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of 14\^C-labeled ertugliflozin in healthy male participants.
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing Non-Small Cell Lung Cancer (NSCLC). The primary hypothesis of this study is that participants with PD-L1 strong NSCLC will have a longer Progression Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) when treated with pembrolizumab than when treated with SOC platinum-based chemotherapies. With Amendment 09 (20 December 2017), once participants have achieved the study objective or the study has ended, participants will be discontinued from this study and enrolled in an extension study to continue protocol-defined assessments and treatment.
This study will test the immunogenicity, safety, and tolerability of VARIVAX™ manufactured with the Varicella Enhanced Process (VEP) compared with the VARIVAX™ 2007 Process. The primary hypotheses being tested are 1)VARIVAX™ VEP will induce varicella-zoster virus (VZV) antibody responses that are non-inferior to those induced by VARIVAX™ 2007 process at 6 weeks after vaccination 1, and 2) VARIVAX™ VEP will induce an acceptable anti-VZV antibody response rate at 6 weeks after vaccination 1.
This study will evaluate the safety and efficacy of combination treatment with grazoprevir (MK-5172) + elbasvir (MK-8742) for cirrhotic and non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV) infection and chronic kidney disease (CKD). The primary study hypothesis is that the proportion of HCV GT1-infected CKD participants within the Immediate Treatment and Intensive Pharmacokinetics (PK) groups achieving a sustained viral response 12 weeks after the end of all study treatment (SVR12) will be \>45%.
This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab (IPI). The primary hypothesis is that these combinations will be sufficiently well-tolerated to permit continued clinical investigation.
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic hepatitis C virus (HCV) infection. Participants will be randomized to one of four different liver ultrasound-guided Fine Needle Aspirate (FNA) schedules (at 4-, 8-, 24-, or 72-hours after the Day 7 dose).
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South Asian countries, especially India which is the largest producer. BCM95 (bioCurcumin) is a combination of a Curcumin extract and oil to enhance the bio-absorbability in humans. BCM95 may enhance and prolong the antioxidant and anti-inflammatory effects of the standard therapy maintaining a good safety profile.
This study will assess the efficacy of a single dose of intravenous (IV) fosaprepitant (MK-0517, EMEND® IV) as salvage therapy when added to a 5-hydroxytryptamine receptor 3 antagonist (5-HT3 RA) and dexamethasone for the prevention of chemotherapy-induced vomiting (CIV) in participants who experienced CIV in the first cycle of moderately emetic chemotherapy (MEC). The primary hypothesis is that there will be no vomiting and no retching in at least 20% of participants during the second cycle of MEC in participants who previously experienced vomiting during the first cycle of MEC.
This study will be conducted in two parts. Part 1 will determine whether administration of adavosertib in combination with topotecan and cisplatin is generally well-tolerated and causes clinical objective responses in patients with cervical cancer. Part 1 will also define the recommended Phase 2 dose and maximum tolerated dose (MTD) of the combination of adavosertib with topotecan and cisplatin. Part 2 of the study will evaluate whether treatment with adavosertib in combination with topotecan and cisplatin causes an improvement in progression-free survival (PFS) compared to treatment with topotecan and cisplatin alone and will further evaluate the tolerability of the combination treatment. The primary hypothesis is the combination of adavosertib, topotecan and cisplatin causes objective radiological responses (assessed per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 criteria) in ≥30% of participants. Due to the early termination of the study by the sponsor, no participants were enrolled in Part 2 of the study.
The objective of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% versus placebo over a two-week treatment period.
This is a multicentric, prospective, observational study on the use of Cetrotide to control the endogenous gonadotrophin levels in Gonal-f stimulated ART treatment cycles in the Asia-Pacific region. The study plans to enrol approximately 1800-2000 subjects over a 9-month period at each participating centre. This observational study is initiated to collect information on the use of Cetrotide (GnRH antagonist) in ART cycles in routine practice across the Asia-Pacific region. The information will allow a better understanding of the current ovarian stimulation regimens that involve Cetrotide in the control of the endogenous gonadotrophin concentrations. The collection of live birth data, though a challenging task, as a secondary endpoint will allow the study to show valuable information on the final objective of ART. To minimize the potential variability due to the different ovarian stimulation agents, the study is to include cycles treated with Gonal-f (recombinant human FSH) since this agent is widely available in the region.
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels
The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.
Nonrandomized, prospective, observational, multi-site registry to assess long-term safety, clinical outcome, deaths, and evolution of viral tropism in HIV subjects who completed or discontinued participation in Phase 2 or 3 clinical trials involving vicriviroc. Subjects will be followed for up to 5 years.
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed Haemophilus Influenzae, type b/Hepatitis B vaccine
A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.
Primary objective: To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days following the second dose of ProQuad® Secondary objectives: * To describe the antibody response rates to measles, mumps, rubella and varicella measured 30 days following the first dose of ProQuad® administered by IM or SC route, * To describe the antibody titres to measles, mumps, rubella and varicella at 30 days following the first dose and at 42 days following the second dose of ProQuad® both administered by IM or SC route, * To describe the safety profile of two doses of ProQuad® both administered by IM or SC route.
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.
This is a long-term, randomized, multi-center, open-label study of infliximab treatment in adults with moderate to severe plaque-type psoriasis. This study is the long-term extension of Study P04271 (NCT00251641); Study P04271 is a Phase 3b, randomized, parallel-group, multicenter, open-label, 26-week study comparing the efficacy and safety of infliximab versus methotrexate in the treatment of adult subjects with moderate to severe plaque-type psoriasis. The objectives of this study are to assess the efficacy and safety of long-term maintenance therapy versus intermittent therapy with 5 mg/kg infliximab in a moderate to severe plaque-type psoriasis population. During an interim safety evaluation of the trial, a higher incidence of serious and severe infusion reactions was observed in the intermittent treatment arm, consisting of a re-induction cycle (maximum of 4 infusions at 0, 2, 6 and 14 weeks) after a period of no treatment compared with the maintenance arm (infusions every 8 weeks without an interruption of treatment). Consequently, the sponsor has terminated the trial. The label will be updated to reflect this new information relating to the use of a re-induction regimen with infliximab.
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling. The study will assess the tolerability, safety and efficacy of the treatment with PegIntron plus Rebetol in this study population. The objective of the study is to collect data on the prevalence of the hepatitis C infections in drug-substituted patients. The study will also compare the feasibility of HCV (Hepatitis C Virus) treatment in patients receiving Subutex® vs other drug substitution pharmacotherapies.
A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.
The primary objective of this current phase I trial is to study the safety and tolerability of an orally administered dosage form of ridaforolimus. This will be accomplished by an ascending dose study of several dosage regimens in patients with advanced malignancies.
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
This is an investigational study to determine the response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid (SAHA), to evaluate PET as an earlier indicator of response to SAHA as assessed by response evaluation criteria in solid tumours (RECIST) criteria and to evaluate the safety and tolerability of oral suberoylanilide hydroxamic acid.
The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin, cisplatin and capecitabine). In addition the study will look at pharmacokinetic (how the the body takes up the drug) and pharmacodynamic parameters (what the drug does in the body).
Authorized distributors - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overvi
Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity … Medicines in Emerging Markets Save April 11, 2011 7:01 am EDT Joint Venture to Apply Proprietary Technologies to Develop Medicines Designed to Enhance Convenience and Improve Compliance Merck & Co., Inc., (NYSE:MRK), a global health care leader, known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd., (“Sun Pharma”) a leading Indian multinational pharmaceutical company, today announced the creation of a joint venture to develop, manufact
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier reg
Manufacturing & Supply | Merck Careers --> Applicant sign-in WORLDWIDE CONTACT US --> --> --> --> We are one company, but we operate under two different corporate brand names. We are known as Merck & Co., Inc., Rahway, New Jersey, USA in the United States, Canada & Puerto Rico. We are known as MSD everywhere else. Company Company overview Stories History Responsibility Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct & compliance Diversity & inclusion Policies & positions Business develop … feedback and support. Once you complete all three rotations, you’re welcome to apply for a position. Opportunities for veterans. As a military veteran, you’ve sacrificed for your country with honor and displayed important personal qualities as leadership, teamwork, discipline, pride, purpose and integrity and given your all for a cause that truly matters. You can put those attributes to work in another setting where lives are on the line at our manufacturing &
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19 - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & complia
💡 Merck Licensing Deal HRS-5346 from Hengrui Pharma Co.,Ltd – A step in cardiovascular innovation | Théo Bouillé LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Collaboration and licensing agreements - Merck Annual Report 2023 Annual Report 2023 Sustainability Report 2023 Other reports Company Expertise Research News Careers Investors Main menu Home To Our Shareholders To Our Shareholders Letter from Belén Garijo The Executive Board Merck Shares Merck in figures Management Report Management Report Fundamental Information about the Group Fundamental Information about the Group Merck Merck Life Science Healthcare Electronics Strategy Strategy Strategy fundamentals & ambition Business Strategies Data & Digital strategy Sustainability Strategy Str
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions … bitor (TKI) and platinum-based therapies. The submission of a biologics license application (BLA) in the U.S. is planned by the end of March 2024 for patritumab deruxtecan, which is based on data from the HERTHENA-Lung01 Phase 2 trial (ClinicalTrials.gov; NCT04619004 ) recently presented at the IASLC 2023 World Conference on Lung Cancer and simultaneously published in the Journal of Clinical Oncology . Ifinatamab deruxtecan is currently being evaluated as monotherapy in
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & co
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and posit … us awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum’s Lifetime Achievement Award. In 2018, Mr. Frazier was named one of the World’s Greatest Leaders by Fortune Magazine and also was named to th … ople. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare. Mr. Frazier received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School. Earnings Conference Call Investors, journalists and the general public may access a live audio webcast of Merck’s earnings call today at 8:00 a.m. EST on Merck’s website at https://www.merck.com/investor-relations/events-and-presentations/ . Institutiona
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms March 25, 2026 | 3 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, SvetaZi Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Veron … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinio … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Merck Declares Record Date and Dividend for the Organon & Co. Spinoff May 7, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Merck Announces Effectiveness of the Form 10 Registration Statement for Organon May 7, 2021 17:01 UTC Merck Announces Effectiveness of the Form 10 Regis … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Merck Abandons $1.3B R&D Center in London, Boots 125 Employees September 11, 2025 | 1 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, Sundry Photography Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plu … to reallocate … resources from the slower growth areas of the business to fully fund into the fast-growing areas of our business,” CEO Rob Davis told investors during the pharma’s Q2 earnings call in July. A few days later, Merck announced an 8% workforce reduction as part of the savings initiative, which affected around 6,000 employees . Merck has implemented several rounds of layoffs this year , terminating 58 employees from its New Jersey headquarters in August and 163 fro … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck’s $3B Savings Push Claims 6,000 Jobs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Merck’s $3B Savings Push Claims 6,000 Jobs August 1, 2025 | 1 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, cagkansayin Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth areas of i … mp;D and used to support the launch of up to 20 new products. “We need to fully fund . . . those launches,” Davis said on the call, referring to both late-stage and commercialization activities for these pipeline assets. “But we want to do it productively and efficiently, and that’s why we’re looking to reallocate . . . resources from the slower growth areas of the business to fully fund into the fast-growing areas of our business.” Merck had already foreshadowed staffing cut … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck Announces Completion of Organon & Co. Spinoff - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Merck Announces Completion of Organon & Co. Spinoff June 3, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer O … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated May 30, 2025 | 3 min read | Annalee Armstrong Twitter LinkedIn Facebook Email Print iStock, Anton Vierietin The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the … al Legal and Policy Center, a right-wing advocacy and watchdog group, brought a proposal to Merck’s May 27 AGM that asked the company to revisit its DEI goals in executive pay incentives. The measure took aim at Merck’s employee and executive annual cash incentives scorecard that weighs some compensation based on sustainability and health access and inclusion of employees. NLPC, which owns enough stock in the pharmaceutical company to have such a measure included in the meeti … ident Donald Trump’s second term. Merck’s board had previously opposed the NLPC proposal, arguing that a review of the programs had already been conducted. Davis repeated this message during the AGM, urging shareholders to reject the proposal. He added that the commitment to DEI initiatives “enables us to fully execute on the scientific method and catalyze contributions and innovations from across our enterprise.” That message echoes the company’s website, which says “inclusi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck October 26, 2022 | 9 min read Twitter LinkedIn Facebook Email Print Merck, known as MSD outside the United States and Canada, announced that the Merck board of directors has unanimously elected Robert M. Davis to serve as chai … us awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum’s Lifetime Achievement Award. In 2018, Ken received the Harvard Law School Association Award, the highest honor given by the prestigious asso … 2021. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare. In 2021, Columbia Business School honored him with the Deming Cup for Operational Excellence, and his peers named Ken Chief Executive magazine’s CEO of the Year. Ken received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around ou … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
After Acceleron deal, new Merck CEO says industry giant is still on the hunt Skip to Main Content Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Devices W … d its perils. [email protected] @matthewherper Tags biotechnology STAT+ To submit a correction request, please visit our Contact Us page . Trending Bipartisan bill seeks to allow direct prescribing of methadone… Bipartisan bill seeks to allow direct prescribing of methadone for opioid addiction Eli Lilly dives into hair loss treatments with investment… Eli Lilly dives into hair loss treatments with investment in AI startup Absci Eli Lilly gave extraordinary
JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity January 13, 2026 | 1 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print hapabapa/Getty Images Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Mond … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D July 29, 2025 | 3 min read | Annalee Armstrong Twitter LinkedIn Facebook Email Print iStock, Deagreez CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savi … e opportunity we have with these 20-plus launches, we will and we need to fully fund behind those launches,” Davis said. That includes supporting Phase III trials and commercialization preparations. “But we want to do it productively and efficiently, and that’s why we’re looking to reallocate … resources from the slower growth areas of the business to fully fund into the fast-growing areas of our business.” That’s why, according to Davis, the program is more of a reallocation … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Business development and licensing (BD&L) - Merck.com Skip to content Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy Merck Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics & compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Re … from certain types of cancer and other diseases. Venture funds The MRL Ventures Fund (MRLV) team invests globally in early-stage, preclinical therapeutics companies focused on delivering innovative therapies to improve patient care. Learn more . Merck Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. L
HANNOVER MESSE Exhibitor 2026: Merck Topics Expo Exhibitors & Products Hall Plan Partner Country Product Innovations Special Displays Startup Area Exhibitor Videos Become an Exhibitor Side Events Event Search Daily Program Center Stage Solution Labs Special Events Become an Exhibitor News News & Articles Podcast Media Library Image Galleries Social Wall Subscribe to Newsletter About us About HANNOVER MESSE After Show Report HANNOVER MESSE worldwide Trade Fair Location Contact us Partners Sustainability Stored Items Visitors Exhibitors Press Login Exhibitors & Products Exhibitors &a
--> 2023 End-of-year Review: Life Science and Healthcare Recruitment top of page Solutions Executive Search Interim Management Market Mapping Compensation Benchmark Board Advisory Leadership & Organisation Assessment Diversity, Equity & Inclusion Practices Aviation & Aerospace Finance Hospitality & Leisure Health Private Equity & Venture Capital Retail and Consumer Goods Sustainability & Energy Transition Transport & Logistics About us Contact us Work for us Meet the team Socially Responsible The Venari Partners Challenge 2026 Insights All Insights Aviation & Ae
Merck & Co, Inc | Access to Medicine Access To Medicine Foundation Who we are What we do Impact Insights & resources News & events Donate Donate Who we are An independent non-profit organisation accelerating progress toward global health equity. About us How we drive change Our strategy 2022 - 2026 Governance Team Funders Annual reports What we do We catalyse progress toward equitable access to essential medicines in low- and middle-income countries through our work across diverse research areas. R&D-based pharma companies Medical gas companies Generic medicine manufacturers Diagno … end-to-end manufacturing of vaccines. *For the 2024 iteration, MSD declined to submit data to the Access to Medicine Index. Opportunities for MSD Improve the quality and broaden the geographic reach of access plans. MSD has access plans that predominantly focus on registering in countries where the company is conducting clinical trials. It can expand its plans, for example, by including equitable pricing and broadening the geographic coverage of these plans to focus on more … its Sustainability Bond Allocation Report in 2023, where proceeds were used to fund projects and partnerships that contribute to the advancement of United Nations Sustainable Development Goals (SDGs), including access to health care and infectious disease research programmes. Merck Foundation committed USD 11mn over six years (2023 – 2028) to the University of New Mexico Health in support of its new initiative to bring high-quality care to an estimated 11mn people living wit … , indicated for HIV and COVID-19, via different procurers, including The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), UNICEF and the US President's Emergency Plan for AIDS Relief (PEPFAR). In addition to supranational agreements, MSD has non-exclusive voluntary licensing agreements for these products to enable generic supply. The company supplies its HPV vaccine Gardasil®4 via Gavi, the Vaccine Alliance. The fourth product, its Ebola virus vaccine ( … scope via the Pat-INFORMED database, including information such as filing date, grant number, grant date and jurisdiction. Additionally, on its website, MSD discloses patent numbers for countries in scope for some of its products. MSD has 2 non-exclusive voluntary licensing agreements to enable generic supply. One of the licensing agreements is f
Exhibitor Detail Skip to content Oct. 28 - 30, 2026 COEX, Seoul English English Korean BIX Sponsor/Booth Inquiry", "Button URL": "https://www.bioplusinterphex.co.kr/en-us/bixinquiry.html", "Button Position": "header" }' data-mixpanel-event='{ "click": "Button Interacted" }' data-rxtag="button" target="_blank"> >BIX Sponsor/Booth Inquiry HOME CONFERENCE AT A GLANCE Conference Sessions Speaker Directory Session Posters EXHIBITOR Exhibiting Information How to Exhibit Sponsorship Program Promotion Items Overseas Contacts VISITOR Visiting Information How to Visit BIX Exhibito
ACRP 2026 | Merck Home Program Program Overview Schedule Tracks Workshops Signature Series Posters Advisory Group Call For Proposals 2027 Experience Community Events Mobile App Marketing Toolkit Explore Orlando Expo+Sponsor Overview Become an Exhibitor Become a Sponsor Download Prospectus Exhibitors Sponsors Group Sales Attendee Profiles Exhibitor & Sponsor Kit Hotel Register Home Program Program Overview Schedule Tracks Workshops Signature Series Posters Advisory Group Call For Proposals 2027 Experience Community Events Mobile App Marketing Toolkit Explore Orlando Expo+Sponsor Overview Become
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Merck - IMMUNOLOGY2026™ Home Register Mobile App Program SCHEDULE AT A GLANCE PRESIDENT’S PROGRAM DISTINGUISHED LECTURES MAJOR SYMPOSIA BLOCK SYMPOSIA GUEST SYMPOSIA CAREER AWARDS CAREER DEVELOPMENT SESSIONS Thursday, April 16 Friday, April 17 Saturday, April 18 COMMITTEE SPONSORED SESSIONS Wednesday, April 15 Thursday, April 16 Friday, April 17 Saturday, April 18 NETWORKING & SOCIAL EVENTS Wednesday, April 15 Thursday, April 16 Friday, April 17 Saturday, April 18 Sunday, April 19 SPONSORED SESSIONS EXHIBIT HALL AAI Booth Theater Poster Walks Findings in 5 EXHIBITOR WORKSHOPS DAILY
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Sponsor Details: 2025 Avoca Quality Consortium Summit x Sponsor Details Name Merck Website https://www.merck.com/ Close
💎 Summit Sponsor Spotlight: Diamond Level A special thank you to Merck, our Diamond Sponsor of the 2026 WomenHeart Summit. Support at this level helps make it possible to convene clinicians, patient leaders, researchers, and advocates working together to advance women’s heart health. From education to advocacy, partnerships like this help drive meaningful change. We’re grateful for your commitment to improving cardiovascular care for women. #WomenHeartSummit #HerHeartHealth2026 #HeartHealthEquity... - WomenHeart: The National Coalition for Women with Heart Disease Facebook Log In WomenHeart:
Your job search results | MSD Careers Applicant sign-in --> --> Menu Close We are one company, but we operate under two different corporate brand names. We are known as Merck & Co., Inc., Rahway, NJ, USA in the United States, Canada & Puerto Rico. We are known as MSD everywhere else. Company Company overview Stories Responsibility Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct & compliance Diversity & inclusion Policies & positions Business development & licensing Suppliers Supplie … e Watch the video Close the popup Curious about our hiring process? Job Search, Application & Interview Tips Frequently Asked Questions Applicant Notice The Physician Payment Sunshine Act (PPSA) Find out more See more See more Not ready to apply? Join our Talent Community to stay connected and receive updates on the latest job opportunities. Join us See more This site is for Residents of Europe, Middle East, Africa, Latin America & Asia Pacific. Residents of the Unite
Join our events at Merck | Merck Careers --> Applicant sign-in WORLDWIDE CONTACT US --> --> --> --> We are one company, but we operate under two different corporate brand names. We are known as Merck & Co., Inc., Rahway, New Jersey, USA in the United States, Canada & Puerto Rico. We are known as MSD everywhere else. Company Company overview Stories History Responsibility Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct & compliance Diversity & inclusion Policies & positions Business developme
Main Sponsor - Merck | 6th BIO Congress 2025 Toggle navigation Register Now Home Programme Important Dates Program Overview Detailed Program Book of Abstracts Evaluation Commissions Contests' Regulations Award Winners Keynote Speakers 2024 Parnas Award Invited Speakers Session Chairs Abstract Submission Sightseeing and Trips Sponsorship Main Sponsor - Merck Gold Sponsors Silver Sponsors Bronze Sponsors Venue Job Market Nauka dla społeczeństwa Local Guide Register Now Fees Registration Form Invitation Letter Regulations Privacy Policy Hotel Mercure**** Jagienka and Zbyszko Stu
Careers | Merck Search results START YOUR JOURNEY WITH US We care passionately about our colleagues, customers, patients, and the planet. That’s why we support and nurture our employees’ ideas, talents, and enthusiasm to advance human progress. Interested? Join us now. DISCOVER MORE ABOUT US Close the popup Loading... Disable Audio Description Enable Audio Description Transcript Work Areas Are you looking for a challenge that’s both rewarding and fulfilling? Start your career at Merck and join a global team with a passion to pioneer. Learn more Watch the video Close the popup Loading... Disabl … popup Loading... Disable Audio Description Enable Audio Description Transcript Application and Tips In this video, Jovana explains our step-by-step application process—from exploring open positions to acing interviews with our HR team and hiring managers. Learn what we value in candidates, including skills, experience, and a mindset that aligns with our company culture. Ready to take the next step? Watch the video Close the popup Loading... Disable Audio Description Enable A